Revivent TC System is used to remove scar tissue on the left ventricle. Credit: Patrick J Lynch, medical illustrator.

European Commission has extended CE Mark for US-based firm BioVentrix’s Revivent TC Transcatheter Ventricular Enhancement System, until May 2024.

The company initially secured the CE Mark for its heart failure treatment system in 2016.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The CE marks allows devices to be marketed across EU member nations.

BioVentrix president and chief executive officer Kenneth Miller said: “The extension of our CE Mark is not only an important milestone for the company but also validates the need for a novel therapy for patients with left ventricular dysfunction who are among the estimated 10 million people in the European Union suffering from heart failure.

“It ensures that physicians will continue to have an important, less invasive therapeutic option for these patients.”

The less invasive ventricular enhancement (LIVE) therapy employs the Revivent TC to remove scar tissue on the left ventricle that occurred due to a heart attack, allowing the healthy portion of the heart to operate.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

BioVentrix stated that the micro-anchors are designed and implanted so that the heart can be made to a natural shape and size, leading to less wall stress and healthier blood flow to body parts.

Percutaneous coronary intervention (PCI) is standard-of-care for restoring blood flow to the heart after a heart attack, which includes a stent implant.

According to a study, 50% of patients treated with PCI were found to develop considerable LV scars, leading to a dilated heart. Enlarged LVs are related to severe heart failure symptoms, higher mortality and frequent re-hospitalisation.

Positive remodelling of the heart has indicated to improve the LV function and reduce heart failure symptoms.

In November, BioVentrix had secured Breakthrough Device Designation status from the US Food and Drug Administration (FDA) for its Revivent TC Transcatheter Ventricular Enhancement System to treat heart failure.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact